At Mirati, we convert possibility into reality by developing best-in-class targeted therapies to improve the lives of patients.
Our scientists are rigorously advancing research and development programs targeting the KRASG12C and KRASG12D mutations.
MRTX1719 is an investigational, internally discovered synthetic lethal PRMT5 inhibitor for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference